1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)

BACKGROUND: IMI/REL is a combination of IMI and the novel class A and class C β-lactamase inhibitor REL. Here we present per-pathogen outcomes from a recent phase 3 clinical trial (RESTORE-IMI 2), in which IMI/REL was shown to be non-inferior to piperacillin/tazobactam (PIP/TAZ) for empiric therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Losada, Maria C, Maniar, Alok, Du, Jiejun, Brown, Michelle L, Young, Katherine, Hilbert, David W, Tipping, Robert, DeRyke, C Andrew, Butterton, Joan R, Paschke, Amanda, Chen, Luke F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776129/
http://dx.doi.org/10.1093/ofid/ofaa439.1415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776129/
http://dx.doi.org/10.1093/ofid/ofaa439.1415

Ejemplares similares